DBVT News and Press, DBV Technologies S.A. From 11/03/25

Chatillion, France, November 3, 2025 DBV Technologies Appoints Industry Leader Kevin Trapp as Chief Commercial Officer DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced the app...

Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of October 31, 2025 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers ) Market : NYSE Euronext Paris ISIN Code: FR 0010417345 ...

Châtillon, France, October 30, 2025 DBV Technologies Announces Appointment of Philina Lee, Ph.D. to Board of Directors DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Market: DBVT), (the “Company” or “DBV”), a clinical-stage...

Châtillon, France, October 30, 2025 DBV Technologies to Participate in Upcoming ACAAI 2025 Annual Scientific Meeting DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT – CUSIP: 23306J309), a clinical-stage biopharmaceutical com...

Châtillon, France, October 28, 2025 DBV Technologies Reports Third Quarter 2025 Financial Results DBV closes Q3 2025 with a cash and cash equivalents balance of $69.8 million, taking cash runway into the third quarter of 2026 DBV Technologies (Euronext: DBV &#...

2025-10-17 10:07:12 ET Shares of DBV Technologies S.A. (NASDAQ: DBVT) traded at a new 52-week high today and are currently trading at $17.57. So far today, approximately 11,688 shares have been exchanged, as compared to an average 30-day volume of 144.19k shares. DBV Technologies S....

2025-10-06 17:14:53 ET More on DBV Technologies DBV Technologies launches $150M ATM offering Seeking Alpha’s Quant Rating on DBV Technologies Historical earnings data for DBV Technologies Financial information for DBV Technologies Read the fu...

Châtillon, France, October 6, 2025 DBV Technologies Announces Sale of approximately $30 million of ADSs Through its At-The-Market (ATM) Program on Nasdaq DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Capital Market: DBVT) (the “Company”...

Châtillon, France, September 18, 2025 DBV Technologies Announces Resignation of Board Member DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Market: DBVT), (the “Company” or “DBV”), a clinical-stage biopharmaceutical company...

2025-09-05 16:59:24 ET More on DBV Technologies Seeking Alpha’s Quant Rating on DBV Technologies Historical earnings data for DBV Technologies Financial information for DBV Technologies Read the full article on Seeking Alpha For further details...